An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
This is an early phase clinical study using NEI-01 as single agent in oncology indication.
This is an open label study and it's divided into two parts.
Part 1: This part is ascending dose design to determine the safety and tolerability of NEI-01
and find out recommended dose of NEI-01 in solid tumor patient.
Part 2: This part is extended dose design to determine the effectiveness of NEI-01 in in
solid tumor and acute myeloid leukemia patients.